timothy sykes logo
SPRC Stock Pops On Volatile Run As Traders Circle Thumbnail

SPRC Stock Pops On Volatile Run As Traders Circle

JACK KELLOGGUPDATED APR. 21, 2026, 9:18 AM ET
Reviewed by Ellis Hobbs Fact-checked by Matt Monaco

SciSparc Ltd. surged as its most impactful news fueled bullish sentiment, and stocks have been trading up by 45.86 percent.

Candlestick Chart

Live Update At 09:17:56 EDT: On Tuesday, April 21, 2026 SciSparc Ltd. stock [NASDAQ: SPRC] is trending up by 45.86%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SciSparc Ltd. (SPRC) sits in that classic small-cap biotech pocket where the story is all about cash, runway, and volatility. On the numbers, SPRC reported roughly $1.31M in revenue, which is tiny, but that’s normal for a clinical-stage-style biotech story that trades on expectations more than current sales.

What jumps out is valuation. With book value per share around $12.99 and the SPRC stock price trading well under that, the market is pricing SciSparc Ltd. at a heavy discount to its accounting equity. Price-to-sales of about 1.9 is low for a speculative biotech, and price-to-book of 0.34 is the kind of number deep-value and momentum traders both pay attention to.

On the balance sheet, SPRC shows about $2.08M in cash and short-term investments against total liabilities near $1.41M. Working capital of roughly $6.1M suggests SciSparc Ltd. is not on immediate life support, even though long-term returns on capital are sharply negative. For traders, that mix — weak profitability, but real assets and cash — often fuels sharp squeezes when volume comes in.

Why Traders Are Watching SPRC Price Action

The SPRC chart is where the story really heats up. On the daily, SciSparc Ltd. has pushed from roughly $3.20–$3.60 into the $4s over recent sessions, and today’s intraday tape shows SPRC trading in the $6–$7 range premarket. That’s a huge percentage move in a short window. This is exactly the type of behavior momentum and breakout traders study every day.

Look at the intraday 5‑minute candles. SPRC spikes from around $5.30 at 04:00 up toward $8.40 by 05:00, then pulls back into the mid‑$7s and later the mid‑$6s. Wide ranges, big wicks, heavy reversals — that’s textbook emotional trading. SciSparc Ltd. is switching hands between early longs, late chasers, and shorts trying to fade the move.

For pattern-focused traders, SPRC is showing repeated push-and-pull around the $6.50–$7.50 band. Each push into the $7s brings selling, while dips into the low $6s find buyers. That kind of tug-of-war can form either a high tight flag or a blowoff top, depending on what volume does next.

Because SciSparc Ltd. is a low-float, low-revenue biotech with a discounted balance sheet, every surge tends to attract day traders scanning for percentage movers. SPRC becomes less about fundamentals in the short term and more about supply and demand: where shorts are trapped, where bagholders want out, and where new breakout buyers step in. When you see SPRC move like this, you treat it as a trading vehicle, not a long-term thesis.

More Breaking News

Conclusion

For active traders, SPRC is a clean case study in how small-cap biotechs trade when volume wakes up. SciSparc Ltd. combines a compressed valuation with a solid, if small, cash cushion and negative long-term returns — the kind of imbalance that can trigger violent re-pricings when the crowd shows up. The recent run from the $3s to the $6–$7 zone has put SPRC squarely on momentum scanners.

The key now is discipline. SPRC’s intraday swings between $6 and $8 show just how fast traders can be rewarded — or punished — if they chase without a plan. Support and resistance are shifting quickly, and any headline, filing, or sector move can flip the script in minutes. SciSparc Ltd. will reward those who study its levels, track volume, and react — not hope.

This is exactly the environment Tim Sykes trains for. As millionaire penny stock trader and teacher Tim Sykes, says, “You must adapt to the market; the market will not adapt to you.”. As he loves to remind traders, “Cut losses quickly. Never risk holding and hoping. Hope is not a strategy.” For SPRC, that mindset is critical. Treat SciSparc Ltd. as a short-term trading opportunity driven by price action, float, and liquidity, and always remember this is educational and research content — not a signal to buy or sell.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:



How much has this post helped you?


Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading SPRC

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”